Overview

Low-Dose Radiation + SBRT + Tislelizumab Plus Platinum-based Chemotherapy in Stage A-B Non-small Cell Lung Cancer

Status:
NOT_YET_RECRUITING

Trial end date:
2028-01-01

Target enrollment:

Participant gender:

Summary

This phase II study aims to evaluate the efficacy and safety of low-dose radiation + SBRT + Tislelizumab plus platinum-based chemotherapy as neoadjuvant therapy for stage II-III non-small cell lung cancer.

Phase:

PHASE2

Details

Lead Sponsor:

Sichuan University

Treatments:

Drug Therapy
Radiosurgery
tislelizumab